Antleron currently develops regenerative products and personalized patient care products. With 3D Systems, the two companies will develop bioprinting solutions using 3D Systems’ 3D printing technologies.
Through the collaboration, the two companies plan to incorporate a variety of technologies to benefit biomedical manufacturing, starting with 3D Systems’s ProJet MJP 2500 and Figure 4 3D printers, along with its existing 21 biocompatible, USP Class VI materials. It will also incorporate 3D Spring and 3DXpert software, as well as post-processing equipment and processes.
“The vision of Antleron is to sustainably bring living therapies into the clinic. 3D printing is key to this endeavor, and we are eager to collaborate with 3D Systems and its experts,” Antleron CEO Jan Schrooten said. “I look forward to the pioneering solutions we’ll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach.”
The goal of the collaboration is to establish a flexible, scalable “Digital Factory” approach that is built on modular, closed parametric processes, according to the company. For example, advancing the way cells and tissues are grown could enable a transition from a static 2D to bioreactor-based 3D cell culture, which can lead to new ways to manufacture functionalized medical implants, vaccines, cell therapies and living tissues.
“3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilizing the 3D Systems’ state of the art printing platforms and materials,” co-founder and chief technology officer at 3D Systems Chuck Hull said. “As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D print, and we look forward to expanding the role 3D Systems will play in these exciting fields.”